Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Advanced methods for dose and regimen finding during drug development:Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014)

Autor: Musuamba, F. T., Manolis, E., Holford, N., Cheung, S. Y. A., Friberg, Lena E, Ogungbenro, K., Posch, M., Yates, J. W. T., Berry, S., Thomas, N., Corriol-Rohou, S., Bornkamp, B., Bretz, F., Hooker, Andrew, Van der Graaf, P. H., Standing, J. F., Hay, J., Cole, S., Gigante, V., Karlsson, K., Dumortier, T., Benda, N., Serone, F., Das, S., Brochot, A., Ehmann, F., Hemmings, R., Rusten, I. Skottheim

Publikováno v: Musuamba, F T, Manolis, E, Holford, N, Cheung, S Y A, Friberg, L, Ogungbenro, K, Posch, M, Yates, J, Berry, S, Thomas, N, Corriol-Rohou, S, Bornkamp, B, Bretz, F, Hooker, A C, Van Der Graaf, P H, Standing, J, Pittaway-Hay, J, Cole, S, Gigante, V, Karlsson, K, Dumortier, T, Benda, N, Serone, F, Das, S, Brochot, A, Falk, E, Hemmings, R & Skottheim Rusten, I 2017, ' Advanced methods for dose and regimen finding during drug development : Summary of the EMA /EFPIA workshop on dose finding (London 4-5 December 2014) ', Clinical Pharmacology & Therapeutics, vol. 6, no. 7 . https://doi.org/10.1002/psp4.12196
CPT: Pharmacometrics & Systems Pharmacology

Inadequate dose selection for confirmatory trials is currently still one of the most challenging issues in drug development, as illustrated by high rates of late-stage attritions in clinical development and postmarketing commitments required by regul

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a20d40a867e767fec9e435f86a311553
https://doi.org/10.1002/psp4.12196

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Losartan and candesartan produce comparable blood pressure reductions but only losartan lowers plasma uric acid in hypertensive patients

Autor: Mejia, A., Jacovides, A., Bernhardi, D.C., Cabrera, W.J., Watanabe, L.A., Barragan, J., Matadamas, N., Mendiola, A., Woo, K.S., Jelaković, Bojan, Grossman, E., Manolis, A., Dumortier, T., Smith, R.D.

To compare antihypertensive effects and uric acid lowering effects of 12 week treatment with losartan or candesartan in patients with mild to moderate hypertension.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::2c899e242acbba308a26ab90d097bf89
https://www.bib.irb.hr/405030